Ann: Positive preliminary data from IHL-675A Ph 1 trial, page-21

INCANNEX (ASX:IHL)

Incannex has completed dosing in its Phase 1 clinical trial to assess multi-use, anti-inflammatory drug IHL-675A, and the company is now arranging Phase 2 studies.

“At this stage, there have been no unexpected adverse events and the drug appears to be well tolerated,” chief scientific officer Dr Mark Bleackley says.

“This gives our team the confidence to take the next steps necessary to commence Phase 2 clinical trials, initially in patients with arthritis, then in patients with lung inflammation and inflammatory bowel disease.”

The company is also preparing for a pre-IND meeting with the FDA on the development of IHL-675A specifically for the treatment of patients with arthritis – which could potentially be a major economic opportunity.

CEO and MD Joel Latham says many people throughout the world are using unapproved CBD or cannabinoids for inflammation-based disorders.

“By undertaking pivotal clinical studies over IHL-675A, and subject to ongoing clinical success, we intend to both disrupt the market for CBD and to open our product to the purview of medical professionals who are eminently more comfortable prescribing FDA approved, pharmaceutical grade products to their patients,” he said.

ASX Biotech Stocks: This brain training app could catch dementia early and Brainchip nabs more patents - *